NEW YORK (GenomeWeb News) – Clinical Data today said that its PGxHealth division will collaborate with the Dana-Farber Cancer Institute to validate the use of genetic variants in the Fc gamma receptors to predict response to trastuzumab (Herceptin) in patients with breast cancer.
PGxHealth will work with researchers at the institute to analyze genetic variants in breast cancer patients enrolled in two independent studies receiving Herceptin along with other drugs in the neoadjuvant setting, or in the setting of metastatic disease. They will evaluate FCGR genotypes and their association with pathological and clinical response to Herceptin.
The partners expect to have preliminary data from those studies by the end of this year.
In addition, the collaboration includes an effort to discover new genetic variants that influence response to Herceptin and may also predict response to other monoclonal antibodies of the IgG1 class.
The collaboration will expand on PGxHealth's FCGR program, which includes its PGxPredict: Rituximab test for determining response to rituximab monotherapy in patients with follicular non-Hodgkin's lymphoma.
"In the future, it may be possible to combine testing for inherited genetic factors with tumor markers, such as HER-2/neu, KRAS and others, to develop diagnostic tests that will be highly predictive of individual response to cancer therapies," Marcia Lewis, VP of biomarker development for PGxHealth said in a statement.